---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-130464"
form_type: "8-K"
ticker: null
cik: "0001466301"
company_name: "Clovis Oncology, Inc."
filed_at: "2023-05-01T23:59:59+00:00"
generated_at: "2026-06-16T04:52:44.883097+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Clovis Oncology completes sale of Rubraca assets to pharma& Schweiz under Chapter 11

## Summary
- On May 1, 2023, Clovis closed the Rubraca asset sale to pharma& Schweiz GmbH, following court approval on April 12.
- Common stockholders are not expected to receive any payment due to senior creditor claims.
- Sale was part of Chapter 11 bankruptcy proceedings initiated in December 2022.

## SEC filing metadata
- accession: 0001193125-23-130464
- form_type: 8-K
- cik: 0001466301
- company_name: Clovis Oncology, Inc.
- filed_at: 2023-05-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1466301/000119312523130464/0001193125-23-130464-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1466301/000119312523130464/d489588d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-130464
- JSON: https://secwatch.observer/filing/0001193125-23-130464.json
- Plain text: https://secwatch.observer/filing/0001193125-23-130464.txt

## Key facts
- M&A Transactions
  Clovis Oncology, Inc. completed a disposition involving pharma& Schweiz GmbH (closed 2023-05-01).
  - Action: disposition
  - Counterparty: pharma& Schweiz GmbH
  - Closing: 2023-05-01
  source text: On May 1, 2023, the Company and Pharma& consummated the Rubraca Sale Transaction.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1466301/000119312523130464/0001193125-23-130464-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.